Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway-Reference-Cited by-同舟云学术

Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway

Published:2018-11-08 Issue:2 Volume:25 Page:635-646
ISSN:1219-4956
Container-title:Pathology & Oncology Research
language:en
Short-container-title:Pathol. Oncol. Res.

Author:

Ou Xi,Zhang Guang-tao,Xu Zhe,Chen Jing-sen,Xie Yong,Liu Ji-Kui,Liu Xiao-Ping

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12253-018-0487-4.pdf

Reference34 articles.

1. Seipel AH, Wiklund F, Wiklund NP, Egevad L (2013) Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch 462(4):429–436. https://doi.org/10.1007/s00428-013-1385-5

2. Lin C, Yan H, Yang J, Li L, Tang M, Zhao X, Nie C, Luo N, Wei Y, Yuan Z (2017) Combination of DESI2 and IP10 gene therapy significantly improves therapeutic efficacy against murine carcinoma. Oncotarget 8(34):56281–56295. https://doi.org/10.18632/oncotarget.17623

3. Shen CC, Cui XY, He Y, Kang YH, Yi C, Yang JL, Gou LT (2015) High phosphorylation status of AKT/mTOR signal in DESI2-reduced pancreatic ductal adenocarcinoma. Pathol Oncol Res 21(2):267–272. https://doi.org/10.1007/s12253-014-9817-3

4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369

5. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol Off J Am Soc Clin Oncol 30(8):777–782. https://doi.org/10.1200/JCO.2011.36.1196

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of potent and selective activity-based probes (ABPs) for the deubiquitinating enzyme USP30;RSC Chemical Biology;2024

2. Insulin receptor tyrosine kinase substrate (IRTKS) promotes the tumorigenesis of pancreatic cancer via PI3K/AKT signaling;Human Cell;2022-09-03

3. Msi1 inhibits cervical cancer cell apoptosis by downregulating BAK through AKT signaling;Journal of Cancer;2021

4. Improvement of cerebral ischemia/reperfusion injury by daucosterol palmitate-induced neuronal apoptosis inhibition via PI3K/Akt/mTOR signaling pathway;Metabolic Brain Disease;2020-05-04